ERAS vs GMED
Erasca, Inc. vs Globus Medical — AI-powered side-by-side comparison
VS
GMED
Globus Medical
71
Buy
| Metric | ERAS | GMED |
|---|
| AI Score |
62
|
71
|
| Price |
$17.67
|
$85.12
|
| P/E Ratio |
-19.27×
|
21.45×
|
| ROE |
-38.3%
|
11.8%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
0.0%
|
68.5%
|
| Debt / Equity |
0.12×
|
0.02×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
48.1
|
75.9
|
| Beta |
0.665
|
0.954
|
| Expected Upside |
—
|
+0.1%
|
AI Committee View
Current Innellis committee reasoning for ERAS versus GMED.
GMED leads by 9 points.
GMED scores 71/100 (Buy) versus ERAS at 62/100 (Buy).
ERAS Committee View
60% agreement
5 analysts
Positive signals support the current rating — vix regime is low -- calm backdrop supports risk-taking. The committee sees sufficient evidence to maintain the constructive view.
Bull Case
- Price structure making higher highs and higher lows — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
- Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock — Risk
Bear Case
- ROE of only -77.0% -- cheap may mean cheap for a reason — Value
- MACD histogram negative -- bearish momentum — Technical
- Bollinger bandwidth of 16.7% signals elevated volatility — Risk
GMED Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is rsi at 76 is in overbought territory. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- RSI at 76 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical